Stable liquid pharmaceutical preparation

Patent metadata

Field	Value
Publication number	US-11730698-B2
Application number	US-201917261145-A
Country	US
Kind code	B2
Filing date	Jul 18, 2019
Priority date	Jul 19, 2018
Publication date	Aug 22, 2023
Grant date	Aug 22, 2023

Abstract

A stable liquid pharmaceutical formulation according to the present invention includes an antibody or antigen-binding fragment thereof, a surfactant, a sugar or a sugar derivative, a buffer, and a stabilizer. The stable liquid pharmaceutical formulation according to the present invention has low viscosity not only when antibody content is low but also when antibody content is high, and exhibits superior long-term storage stability based on superior stability observed under accelerated conditions and harsh conditions.

First claim

The invention claimed is:

1. A stable liquid pharmaceutical formulation, comprising:
(A) an antibody or antigen-binding fragment thereof;
(B) a surfactant;
(C) a sugar or a sugar derivative;
(D) a buffer; and
(E) a stabilizer; wherein
(A) the antibody comprises an antibody that binds to HER2;
a concentration of (A) the antibody or antigen-binding fragment thereof is 250 mg/ml or less; and
the stable liquid pharmaceutical formulation does not comprise histidine.

2. The stable liquid pharmaceutical formulation of claim 1 , wherein (A) the antibody comprises trastuzumab, pertuzumab, or a mixture thereof.

3. The stable liquid pharmaceutical formulation of claim 1 , wherein (A) the antibody comprises a humanized IgG monoclonal antibody.

4. The stable liquid pharmaceutical formulation of claim 1 , wherein (A) the antibody or antigen-binding fragment thereof comprises:
a light-chain variable region comprising a CDR1 domain comprising an amino acid sequence of SEQ ID NO:1, a CDR2 domain comprising an amino acid sequence of SEQ ID NO:2, and a CDR3 domain comprising an amino acid sequence of SEQ ID NO:3; and
a heavy-chain variable region comprising a CDR1 domain comprising an amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising an amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising an amino acid sequence of SEQ ID NO:6.

5. The stable liquid pharmaceutical formulation of claim 1 , wherein (A) the antibody or antigen-binding fragment thereof comprises a light-chain variable region comprising an amino acid sequence of SEQ ID NO:7 and a heavy-chain variable region comprising an amino acid sequence of SEQ ID NO:8.

6. The stable liquid pharmaceutical formulation of claim 1 , wherein (A) the antibody comprises a light chain comprising an amino acid sequence of SEQ ID NO:9 and a heavy chain comprising an amino acid sequence of SEQ ID NO:10.

7. The stable liquid pharmaceutical formulation of claim 1 , wherein (B) the surfactant comprises polysorbate, poloxamer or a mixture thereof.

8. The stable liquid pharmaceutical formulation of claim 1 , wherein (B) the surfactant comprises Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 80, or a mixture of two or more thereof.

9. The stable liquid pharmaceutical formulation of claim 1 , wherein (B) the surfactant comprises Polysorbate 80.

10. The stable liquid pharmaceutical formulation of claim 1 , wherein a concentration of (B) the surfactant is 0.02 to 0.1% (w/v).

11. The stable liquid pharmaceutical formulation of claim 1 , wherein (C) the sugar comprises a monosaccharide, a disaccharide, an oligosaccharide, a polysaccharide, or a mixture of two or more thereof, and (C) the sugar derivative comprises a sugar alcohol, a sugar acid, or a mixture thereof.

12. The stable liquid pharmaceutical formulation of claim 1 , wherein (C) the sugar or the sugar derivative comprises sorbitol, mannitol, trehalose, sucrose, or a mixture of two or more thereof.

13. The stable liquid pharmaceutical formulation of claim 1 , wherein a concentration of (C) the sugar or the sugar derivative is 1 to 10% (w/v).

14. The stable liquid pharmaceutical formulation of claim 1 , wherein (D) the buffer comprises acetate.

15. The stable liquid pharmaceutical formulation of claim 1 , wherein a content of (D) the buffer is 1 to 50 mM.

16. The stable liquid pharmaceutical formulation of claim 1 , wherein (E) the stabilizer comprises methionine, aspartic acid, proline, or a mixture of two or more thereof.

17. The stable liquid pharmaceutical formulation of claim 1 , wherein (E) the stabilizer comprises methionine.

18. The stable liquid pharmaceutical formulation of claim 1 , wherein a content of (E) the stabilizer is 5 to 100 mM.

19. The stable liquid pharmaceutical formulation of claim 1 , having a pH of 4.5 to 6.0.

20. The stable liquid pharmaceutical formulation of claim 1 , which does not comprise NaCl, KCl, NaF, KBr, NaBr, Na 2 SO 4 , NaSCN, K 2 SO 4 , or a mixture thereof.

21. The stable liquid pharmaceutical formulation of claim 1 , comprising:
(A) 250 mg/ml or less of an antibody or antigen-binding fragment thereof comprising a light-chain variable region comprising a CDR1 domain comprising an amino acid sequence of SEQ ID NO:1, a CDR2 domain comprising an amino acid sequence of SEQ ID NO:2, and a CDR3 domain comprising an amino acid sequence of SEQ ID NO:3, and a heavy-chain variable region comprising a CDR1 domain comprising an amino acid sequence of SEQ ID NO:4, a CDR2 domain comprising an amino acid sequence of SEQ ID NO:5, and a CDR3 domain comprising an amino acid sequence of SEQ ID NO:6;
(B) 0.02 to 0.1% (w/v) of a surfactant;
(C) 1 to 10% (w/v) of a sugar or a sugar derivative;
(D) 1 to 50 mM of a buffer; and
(E) 5 to 100 mM of a stabilizer.

22. A method for administration of the stable liquid pharmaceutical formulation of claim 1 , comprising:
administering to a subject the stable liquid pharmaceutical formulation by intravenous administration or subcutaneous administration.

23. The stable liquid pharmaceutical formulation of claim 1 , which does not undergo either or both of a reconstitution step and a dilution step before use.

24. A pre-filled syringe filled with the stable liquid pharmaceutical formulation of claim 1 .

25. An auto-injector comprising therein the pre-filled syringe of claim 24 .

Assignees

• Celltrion Inc

Inventors

• Kim So Young
• Shin Yeon Kyeong
• Kang Hye Young
• Kim Kwang Woo
• Oh Jun Seok
• Kim Su Jung
• Lee Joon Won
• Han Won Yong
• Lee Jae Bin
• Roh Ji Won
• Kwak Ji Min

Classifications

• A61K39/001106

  Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4 · CPC title

• A61K9/08 Primary

  Solutions {(composition of solutions A61K47/00)} · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61K47/10

  Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers · CPC title